INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Safety Study
2021-003637-11
Phase 1 other active
Quick answer
INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Safety Study for Patients with malignant peritoneal mesothelioma is a Phase 1 program (other) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- Patients with malignant peritoneal mesothelioma
- Phase
- Phase 1
- Modality
- other
- Status
- active